Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Uterine fibroids, smooth muscle tumours of the uterus, are found in at least 25 to 35% of women over the age of 35 years. Although some of these tumours are asymptomatic, up to 50% cause symptoms severe enough to warrant therapy and surgery is the standard treatment. Fibroid growth is stimulated by oestrogen and gonadotropin releasing hormone agonists (GnRHa) which induce a state of hypoestrogenism have been investigated as a potential treatment. GnRHa treatment causes fibroids to shrink but cannot be used long term because of unacceptable symptoms and bone loss. Therefore, GnRHa may be useful pre-operatively both to reduce fibroid and uterine volume and control bleeding. OBJECTIVES: The objective of this review is to evaluate the role of pre-treatment with gonadotropin releasing hormone (GnRH) analogues prior to a major surgical procedure, either hysterectomy or myomectomy, for uterine fibroids. SEARCH STRATEGY: Electronic searches for relevant randomised controlled trials of the Cochrane Menstrual Disorders and Subfertility Group Register of Trials, MEDLINE, EMBASE, the National Research Register, the National Library of Medicine's Clinical Trials Register and Current Contents were performed. Attempts were also made to identify published trials from citation lists of review articles and direct contact with drug companies for unpublished trials. In most cases, the first author of each included trial was contacted for additional information. The search was updated in October 2000. SELECTION CRITERIA: The inclusion criteria were randomised comparisons of GnRH analogue treatment versus placebo, no treatment, or other medical therapy prior to surgery, either myomectomy or hysterectomy, for uterine fibroids. DATA COLLECTION AND ANALYSIS: Twenty-six RCTs were identified that fulfilled the inclusion criteria for this review. The reviewers extracted the data independently and odds ratios for dichotomous outcomes and weighted mean differences for continuous outcomes were estimated from the data of fourteen trials where GnRH analogue treatment was compared with no pre-treatment and six trials where GnRH analogue treatment was compared with placebo. Three trials are awaiting assessment because the data were not in a suitable form for extraction or they are awaiting translation. Two trials have been excluded because the data were not in a suitable form for extraction and the authors were not able to provide additional information. One RCT compared GnRHa pre-treatment with lynestrenol pre-treatment. Results from pre-operative outcomes were combined for both types of surgery but results from intra- and post-operative outcomes were reported separately for myomectomy and hysterectomy. Subgroup analysis was performed according to type of control group, no pre-treatment or placebo, and for some outcomes there were additional subgroup analyses according to size of the uterus in gestational weeks. MAIN RESULTS: Pre- and post-operative haemoglobin (Hb) and haematocrit (HCT) were significantly improved by GnRH analogue therapy prior to surgery, and uterine volume, uterine gestational size and fibroid volume were all reduced. Pelvic symptoms were also reduced but some adverse events were more likely during GnRH analogue therapy. Hysterectomy appeared to be easier after pre-treatment with GnRH analogue therapy; there was reduced operating time and a greater proportion of hysterectomy patients were able to have a vaginal rather than an abdominal procedure. Duration of hospital stay was also reduced. Blood loss and rate of vertical incisions were reduced for both myomectomy and hysterectomy. Evidence of increased risk of fibroid recurrence after GnRH analogue pre-treatment in myomectomy patients was equivocal and few data were available to assess change in post-operative fertility. Lynestrenol did not offer any advantage over GnRH analogue therapy before fibroid surgery. The increased costs associated with GnRH analogue therapy were not assessed. REVIEWER'S CONCLUSIONS: The use of GnRH analogues for 3 to 4 months prior to fibroid surgery reduce both uterine volume and fibroid size. They are beneficial in the correction of pre-operative iron deficiency anaemia, if present, and reduce intra-operative blood loss. If uterine size is such that a mid-line incision is planned, this can be avoided in many women with the use of GnRH analogues. For patients undergoing hysterectomy, a vaginal procedure is more likely following the use of these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uterine leiomyomata: etiology, symptomatology, and management
Wallach, E. E., Buttram, V. C., & Reiter, R. C. (1981) · Fertility and Sterility · doi:10.1016/s0015-0282(16)45789-4 · Cited by 1,560
The epidemiology of hysterectomy: findings in a large cohort study
VESSEY, M. P., VILLARD‐MACKINTOSH, L., MCPHERSON, K., COULTER, A., & YEATES, D. (1992) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1992.tb13758.x · Cited by 466
Ultrasound in Obstetrics and Gynaecology
Merz, E., Bahlmann, F., BERNASCHEK, G., Bollmann, R., Chaoui, R., Deutinger, J., Eichhorn, K., Ertan, K., Flock, F., Grab, D., et al. (1983) · Cited by 419
Ultrasound in Obstetrics and Gynecology
Bagley, A. (1994) · Investigative Radiology · doi:10.1097/00004424-199403000-00033 · Cited by 159
Friedman, A. J., Lobel, S. M., Rein, M. S., & Barbieri, R. L. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90667-v · Cited by 149
Friedman, A. J., Rein, M. S., Harrison-Atlas, D., et al. (1989) · Fertility and Sterility · doi:10.1016/s0015-0282(16)61022-1 · Cited by 148
Reinsch, R. C., Murphy, A. A., Morales, A. J., & Yen, S. S. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70332-9 · Cited by 123
Treatment with GnRH agonists before myomectomy and the risk of short‐term myoma recurrence
Fedele, L., Vercellini, P., Bianchi, S., et al. (1990) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb01824.x · Cited by 114
Campo, S. (1999) · Human Reproduction · doi:10.1093/humrep/14.1.44 · Cited by 111
MATTA, W. H. M., Shaw, R. W., & NYE, M. (1989) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1989.tb01663.x · Cited by 104
A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas
Stovall, T. G., Ling, F. W., Henry, L. C., & Woodruff, M. R. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)91419-w · Cited by 98
Stovall, T. G., Muneyyirci‐Delale, O., TTJR, R. S., et al. (1995) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00102-w · Cited by 97
Zullo, F., Pellicano, M., Stefano, R. D., et al. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70635-0 · Cited by 87
Pre-operative gonadotrophin-releasing hormone agonist treatment in surgery for uterine leiomyomata
Golan, A., Bukovsky, I., Pansky, M., et al. (1993) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a138070 · Cited by 51
Vercellini, P., Crosignani, P. G., Mangioni, C., Imparato, E., Ferrari, A. G., & Giorgi, O. D. (1998) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb09967.x · Cited by 49
Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study
Benagiano, G., Kivinen, S., Fadini, R., Cronjé, H. S., Klintorp, S., & van der Spuy, Z. M. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58443-x · Cited by 39
Mechanism of LHRH Analogue Action in Uterine Fibroids
Shaw, R. W. (2008) · Hormone Research · doi:10.1159/000181332 · Cited by 36
Ylikorkala, O., Tiitinen, A. E., Hulkko, S., Kivinen, S., & Nummi, S. (1995) · PubMed · Cited by 20
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103182 · Cited by 680
Epidemiology and management of uterine fibroids
Giuliani, E., As‐Sanie, S., & Marsh, E. E. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13102 · Cited by 674
The Management of Uterine Leiomyomas
Vilos, G. A., Allaire, C., Laberge, P.-Y., Leyland, N., Vilos, A. G., Murji, A., & Chen, I. (2015) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30338-8 · Cited by 642
Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Donnez, J., Tomaszewski, J., Vázquez, F., Bouchard, P., Lemieszczuk, B., Baró, F., Nouri, K., Selvaggi, L., Sodowski, K., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103180 · Cited by 607
Metadata
- Authors
- Lethaby, A., Vollenhoven, B., & Sowter, M. C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2001-04-23
- Issue
- 2
- Pages
- CD000547-CD000547
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1560363176
- Cited by
- 356
- References
- 18
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.